Biovie Inc.BIVI

BioVie Inc. is a clinical-stage biopharma company chasing orphan-drug prizes and fast-track nods while its cash register stays stubbornly silent. The company’s latest SEC S-1 filing, published on July 17, 2026, confirms that the last reported share price on Nasdaq was $1.77 and that the firm’s pipeline hinges on products like BIV201, a candidate with Orphan Drug Designation but no marketing approval or revenue to show for it. The filing is explicit: “there is no assurance that BioVie will be the first to obtain marketing” for these candidates, a rare moment of candour in a sector that usually markets hope like certainty.

The company’s public pages are polished: clinical-trial graphics, pipeline roadmaps, and product images that look like they belong in a polished brochures rather than on a balance sheet showing $5.3 million in net losses for the quarter ending March 31, 2026. The tension isn’t subtle; it’s the gap between the website’s promise of “transformational assets” and the 10-Q’s blunt admission that operating cash burned $14.9 million in the same period, while R&D costs clocked in at $3.2 million. The firm’s cash and equivalents stood at $13.1 million on March 31, a figure that would cover roughly two weeks of New York City rent-hardly the runway required for a biotech with no approved product.

The S-1 filing also reveals that BioVie’s shares trade under the ticker BIVI on Nasdaq, a detail that matters only if shareholders are still awake enough to care. The document repeats the $1.77 per share price as the last reported sales price, a figure that now feels less like a valuation and more like a placeholder while the company shops a $100 million shelf registration filed on June 18, 2026, under an S-3 that lets it sell new equity whenever the mood strikes. The 13D filed on March 25, 2026, shows a single large beneficial owner, a structure that turns the management desks spotlight toward optics and incentives rather than operating performance.

For readers who prefer numbers to narratives, the May 11, 2026, 10-Q offers the cleanest ledger: net loss attributable to parent was $5.3 million, operating loss was $5.4 million, assets totalled $17.5 million, liabilities $1.9 million, and stockholders’ equity sat at $15.6 million. Cash used in operating activities was $14.9 million, and diluted EPS clocked in at a polite $-0.70 with 7.5 million diluted shares outstanding. These are not rounding errors; they are the ledger entries for a company that has yet to earn a dime.

If you’re hunting for charts, the officially supplied evidence stops at the SEC filings and product pages, so there are no trading-view candles or analyst estimates in this file. The company’s own sources-clinical-trial pages, pipeline overviews, and product images-exist to illustrate the promise, not to prove the profit. The regulatory path is mapped in FDA guidance received in June 2023 and December 2024, but guidance isn’t approval, and approval isn’t revenue. Until BioVie ships a product or signs a commercial deal, the balance sheet remains the only document that tells the real story.

The official sources also include a company facts JSON from the SEC, an EDGAR filing index for BioVie Inc. (CIK 1580149), and a submissions JSON-all useful for the diligent researcher but silent on revenue, approvals, or customer counts. The clinical-trials rail shows active studies, the pipeline rail lists candidates, and the product rail supplies images of hopeful molecules, but none of these sources supply the one line that would change the file: “We sold something and collected cash.” Until that line appears, the file’s tension stays unresolved.